CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Epiduo gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01188538
NCT01188538Phase 4Completed

Anti P. Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel in the Treatment of Subjects With Acne Vulgaris

Galderma R&D·interventional·Posted Aug 25, 2010·Updated Feb 18, 2021

In Brief

A Phase 4 clinical trial evaluating Epiduo gel and BPO for Acne Vulgaris. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesPoland
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2010
Enrollment StartMar 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.9 years ago

Interventions

Epiduo geldrug

Once daily application on the face in the evening for 12 weeks

BPOdrug

Once daily application on the face in the evening for 12 weeks